FUJIFILM Holdings Corporation has reported a strong set of results for the fiscal year ended March 31, 2026, posting record performance across key financial metrics and signaling continued momentum into the next fiscal year.
For the full year, the company delivered revenue of JPY 3,357.0 billion, up 5.0% year-over-year. Operating income rose 6.1% to JPY 350.2 billion, while net income attributable to FUJIFILM Holdings increased 6.0% to JPY 276.7 billion. The company also announced an annual dividend of JPY 70 per share for FY2025, marking its 16th consecutive annual increase.
Looking ahead, FUJIFILM is forecasting another record year for the fiscal year ending March 2027, with revenue expected to reach JPY 3.47 trillion. Operating income is projected to rise 4.2% to JPY 365.0 billion, and net income is forecast at JPY 280.0 billion.
The company also expects to raise its annual dividend to JPY 75 per share, extending its streak of dividend growth to 17 consecutive years.
However, the outlook excludes potential volatility from raw material and energy costs amid geopolitical tensions in the Middle East, citing significant uncertainty in future conditions.
“Our focus is on achieving sustainable growth by expanding our semiconductor materials business and scaling production capacity in the Bio CDMO business. We are committed to accelerating progress toward the goals outlined in VISION2030 and establishing Fujifilm as a collection of global leading businesses,” said Teiichi Goto, president and chief executive officer, representative director, FUJIFILM Holdings Corporation.
In the fourth quarter alone, FUJIFILM posted revenue of JPY 927.3 billion, up 6.8% year-over-year. Operating income declined 4.8% to JPY 101.8 billion, while net income rose 5.0% to JPY 83.4 billion.
Segment performance was mixed but highlighted strong growth in high-margin technology areas.
Healthcare revenue rose 5.4% to JPY 333.6 billion, though operating income fell sharply 34.7% to JPY 29.7 billion due to rising raw material costs, particularly silver. Strength in endoscopes, Bio CDMO operations in Denmark, and recovering cell culture media demand supported top-line growth.
Electronics was a standout performer, with revenue jumping 27.4% to JPY 127.5 billion and operating income surging 74.0% to JPY 30.7 billion, driven by surging demand for semiconductor materials linked to generative AI and strong sales in display materials and data tapes.
Business Innovation posted softer results, with revenue down 3.5% to JPY 324.8 billion and operating income down 15.4% to JPY 27.0 billion, weighed by weakness in Asia-Pacific office solutions and lower demand for printing plates in Europe.
Imaging remained a bright spot, with revenue rising 22.6% to JPY 141.4 billion and operating income edging up 1.1% to JPY 24.5 billion. Growth was fueled by strong demand for instax products such as instax mini 12, instax mini Evo, instax WIDE 400, instax Link 3, and instax WIDE Evo, along with strong sales of new digital cameras including the GFX100RF, X half, X-E5, and X-T30 III.
The company said it remains focused on scaling its high-growth healthcare and electronics businesses while maintaining steady expansion in imaging as part of its broader VISION2030 strategy.
